Ultra-Performance LC-MS System Approved for Clinical Applications in China
By LabMedica International staff writers Posted on 03 Jul 2014 |
An ultra-performance liquid chromatography – mass spectrometry (UPLC-MS) system has been approved by the Chinese Food and Drug Administration (CFDA) as a medical device for routine diagnostic applications and for screening of neonatal metabolites diseases.
The CFDA approval was granted for the ACQUITY UPLC TQD from Waters Corporation (Milford, MA, USA). A continuation of Waters' commitment to China and to growing clinical LC-MS applications worldwide, this represents the second Waters' mass spectrometer approved for in vitro diagnostic (IVD) applications in China (in 2008, the CFDA (formerly SFDA) approved a neonatal screening solution inclusive of the Waters Quattro micro mass spectrometer).
An UPLC tandem quadrupole mass spectrometry (UPLC/MS/MS) system, the ACQUITY UPLC TQD (tandem quadrupole detector) is a benchtop, ultra-compact, tandem-quadrupole, mass detector-based system designed for routine UPLC/MS/MS analyses and quantitative applications, featuring high levels of MS selectivity, robustness, speed, and accuracy. To maximize the analytical advantages of UPLC, the ACQUITY TQD operates at the highest data acquisition rates. Integrated with the Waters ACQUITY UPLC System, the ACQUITY TQD gives class-leading analytical detection limits, resolution, and sample throughput.
"The approval by the CFDA of ACQUITY UPLC MS/MS system as a medical device is significant for two reasons. First and most importantly, this registration opens the door for millions of Chinese citizens to benefit from the gold standard of LC-MS diagnostic analysis," said Dr. Rohit Khanna, vice president of Worldwide Marketing and Informatics at Waters, "Secondly, this commitment to China's analytical scientists and laboratories reinforces Waters' strategy of expanding applications of our core chromatography and mass spectrometry technologies throughout the world. As of this decision by the CFDA, the ACQUITY UPLC, MS/MS system is registered as a medical device in 29 countries plus the European Economic Area, which includes an additional 30 countries."
Related Links:
Waters Corporation
ACQUITY UPLC TQD
The CFDA approval was granted for the ACQUITY UPLC TQD from Waters Corporation (Milford, MA, USA). A continuation of Waters' commitment to China and to growing clinical LC-MS applications worldwide, this represents the second Waters' mass spectrometer approved for in vitro diagnostic (IVD) applications in China (in 2008, the CFDA (formerly SFDA) approved a neonatal screening solution inclusive of the Waters Quattro micro mass spectrometer).
An UPLC tandem quadrupole mass spectrometry (UPLC/MS/MS) system, the ACQUITY UPLC TQD (tandem quadrupole detector) is a benchtop, ultra-compact, tandem-quadrupole, mass detector-based system designed for routine UPLC/MS/MS analyses and quantitative applications, featuring high levels of MS selectivity, robustness, speed, and accuracy. To maximize the analytical advantages of UPLC, the ACQUITY TQD operates at the highest data acquisition rates. Integrated with the Waters ACQUITY UPLC System, the ACQUITY TQD gives class-leading analytical detection limits, resolution, and sample throughput.
"The approval by the CFDA of ACQUITY UPLC MS/MS system as a medical device is significant for two reasons. First and most importantly, this registration opens the door for millions of Chinese citizens to benefit from the gold standard of LC-MS diagnostic analysis," said Dr. Rohit Khanna, vice president of Worldwide Marketing and Informatics at Waters, "Secondly, this commitment to China's analytical scientists and laboratories reinforces Waters' strategy of expanding applications of our core chromatography and mass spectrometry technologies throughout the world. As of this decision by the CFDA, the ACQUITY UPLC, MS/MS system is registered as a medical device in 29 countries plus the European Economic Area, which includes an additional 30 countries."
Related Links:
Waters Corporation
ACQUITY UPLC TQD
Read the full article by registering today, it's FREE!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
- Free digital version edition of LabMedica International sent by email on regular basis
- Free print version of LabMedica International magazine (available only outside USA and Canada).
- Free and unlimited access to back issues of LabMedica International in digital format
- Free LabMedica International Newsletter sent every week containing the latest news
- Free breaking news sent via email
- Free access to Events Calendar
- Free access to LinkXpress new product services
- REGISTRATION IS FREE AND EASY!
Sign in: Registered website members
Sign in: Registered magazine subscribers
Latest Clinical Chem. News
- 3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models
- POC Biomedical Test Spins Water Droplet Using Sound Waves for Cancer Detection
- Highly Reliable Cell-Based Assay Enables Accurate Diagnosis of Endocrine Diseases
- New Blood Testing Method Detects Potent Opioids in Under Three Minutes
- Wireless Hepatitis B Test Kit Completes Screening and Data Collection in One Step
- Pain-Free, Low-Cost, Sensitive, Radiation-Free Device Detects Breast Cancer in Urine
- Spit Test Detects Breast Cancer in Five Seconds
- Electrochemical Sensors with Next-Generation Coating Advances Precision Diagnostics at POC
- First-Of-Its-Kind Handheld Device Accurately Detects Fentanyl in Urine within Seconds
- New Fluorescent Sensor Array Lights up Alzheimer’s-Related Proteins for Earlier Detection
- Automated Mass Spectrometry-Based Clinical Analyzer Could Transform Lab Testing
- Highly Sensitive pH Sensor to Aid Detection of Cancers and Vector-Borne Viruses
- Non-Invasive Sensor Monitors Changes in Saliva Compositions to Rapidly Diagnose Diabetes
- Breakthrough Immunoassays to Aid in Risk Assessment of Preeclampsia
- Urine Test for Monitoring Changes in Kidney Health Markers Can Predict New-Onset Heart Failure
- AACC Releases Comprehensive Diabetes Testing Guidelines